We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+35.24%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$9.32B
AUM Growth
+$2.47B
(+36%)
Cap. Flow
+$393M
Cap. Flow
% of AUM
4.22%
Top 10 Holdings %
Top 10 Hldgs %
43.12%
Holding
161
New
36
Increased
24
Reduced
14
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVTA
Invitae Corporation
NVTA
|
+$348M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$229M |
| 3 |
Atea Pharmaceuticals
AVIR
|
+$100M |
| 4 |
C4 Therapeutics
CCCC
|
+$91.6M |
| 5 |
KRON
Kronos Bio
KRON
|
+$87.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$190M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$112M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
+$77.6M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$61.6M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$36.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.2% |
| 2 | Financials | 0.33% |
| 3 | Industrials | 0.29% |
| 4 | Materials | 0.22% |
| 5 | Consumer Discretionary | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Verrica Pharmaceuticals
VRCA
$89M
| $39.3M | 0.42% |
341,041
| – | – |
|
|
SAGE
52
DELISTED
Sage Therapeutics
SAGE
| $38.1M | 0.41% |
+440,000
| New | +$32.4M |
|
|
LYRA
53
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $36.7M | 0.39% |
64,451
| – | – |
|
54
VYNE Therapeutics
VYNE
| $36.1M | 0.39% |
6,355
| – | – |
|
55
Cogent Biosciences
COGT
$6.76B
| $35.8M | 0.38% |
3,188,750
+1,200,000
| +60% | +$13.2M |
|
|
NEPT
56
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $34.7M | 0.37% |
15,868
+1,984
| +14% | +$5.1M |
|
57
ADMA Biologics
ADMA
$2.02B
| $32.3M | 0.35% |
16,584,802
| – | – |
|
|
RNAM
58
DELISTED
Avidity Biosciences
RNAM
| $31.5M | 0.34% |
1,235,818
| – | – |
|
|
RAPT
59
DELISTED
RAPT Therapeutics
RAPT
| $31.2M | 0.33% |
+197,185
| New | +$42.9M |
|
|
ISEE
60
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $31M | 0.33% |
4,482,713
+1,001,282
| +29% | +$6.41M |
|
|
SILK
61
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $29.3M | 0.31% |
465,100
-55,000
| -11% | -$3.41M |
|
62
Allogene Therapeutics
ALLO
$625M
| $28.9M | 0.31% |
1,143,790
| – | – |
|
63
MacroGenics
MGNX
$233M
| $28.8M | 0.31% |
1,261,060
-30,121
| -2% | -$693K |
|
64
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
| $28.2M | 0.3% |
200,000
| – | – |
|
65
Veru
VERU
$35.5M
| $28.1M | 0.3% |
325,000
+160,000
| +97% | +$6.62M |
|
|
ACCD
66
DELISTED
Accolade Inc
ACCD
| $27.3M | 0.29% |
626,591
+333,453
| +114% | +$14.8M |
|
|
CNCE
67
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $27.2M | 0.29% |
2,150,641
| – | – |
|
68
Immatics
IMTX
$1.23B
| $27M | 0.29% |
2,500,000
| – | – |
|
69
Regeneron Pharmaceuticals
REGN
$72.9B
| $26.7M | 0.29% |
55,175
+50,175
| +1,004% | +$27.1M |
|
70
Pulmonx
LUNG
$52.8M
| $26.6M | 0.29% |
+385,000
| New | +$18.9M |
|
|
FUSN
71
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $26.3M | 0.28% |
2,235,983
| – | – |
|
72
Establishment Labs
ESTA
$2.71B
| $26.2M | 0.28% |
696,633
+18,000
| +3% | +$474K |
|
73
AnaptysBio
ANAB
$1.54B
| $25.7M | 0.28% |
+1,195,336
| New | +$29M |
|
74
4D Molecular Therapeutics
FDMT
$502M
| $24.9M | 0.27% |
+600,256
| New | +$24.8M |
|
|
ONEM
75
DELISTED
1Life Healthcare
ONEM
| $22.7M | 0.24% |
519,844
+240,000
| +86% | +$8.2M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, Perceptive Advisors held 161 positions worth $9.32B, up 36% from $6.85B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Perceptive Advisors deployed $393M of net new capital in Q4 2020, opening 36 new positions and adding to 24 existing holdings. Its largest new stake was Invitae Corporation: 7,284,466 shares worth $305M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $36.5M trimmed.
- Perceptive Advisors's largest Q4 2020 buy was Invitae Corporation: 7,284,466 shares worth $305M.
- Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2020, an estimated $55.8M increase.
- Perceptive Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $36.5M.
- Perceptive Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $190M.
- Perceptive Advisors's ten largest holdings make up 43% of its $9.32B portfolio in Q4 2020.
- Perceptive Advisors opened 36 new positions and closed 22 in Q4 2020.
- Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $9.32B.
Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.